Current pharmacotherapies for smoking have only modest efficacy with failure rates of up to 90%. One potential target for new pharmacotherapies is the orexin/hypocretin system, a hypothalamic neuropeptide system involved in arousal, appetite and reward. The orexin system has been suggested as a potential therapeutic target for nicotine addiction because there are orexin/nicotine interactions following both acute and chronic nicotine administration, preclinical findings in animal models of nicotine addiction and some correlational studies in humans. Acute orexin administration activates cholinergic neurons and acute nicotine administration activates orexin neurons, while chronic nicotine causes an upregulation in orexin peptides and receptors while decreasing the availability of orexin binding sites. A small number of preclinical studies in animal models of nicotine addiction have found effects of orexin antagonists in reducing nicotine self-administration and/or reinstatement behavior, but results are not always entirely consistent between studies. A few human studies have found negative correlations between orexin levels and measures of nicotine craving in humans, or genetic associations between hypocretin receptor polymorphism and nicotine dependence. However, further research is required to reconcile discrepancies in the preclinical literature and to understand the role of the orexin system in nicotine dependence before clinical trials can be proposed.
. Thus, orexin signaling is thought to be excitatory with a Gαq-mediated signaling cascade, but with the potential for interactions with co-transmitters and heteromeric receptor complexes.
Neuroanatomical and Molecular Interactions
Acute Nicotine and Orexin
The orexin system has been suggested as a potential therapeutic target because of the neuroanatomical and molecular interactions between the cholinergic and orexinsystems.
Interactions occur following both acute and chronic nicotine administration. Cholinergic neurons are activated by OX-A application (Fadel, Pasumarthi, & Reznikov, 2005) and orexin neurons are activated by acute systemic nicotine administration ( Figure 3 ; Pasumarthi, Reznikov, & Fadel, 2006) . Importantly, this activation, as measured by c-Fos immunohistochemistry, appears to be specific in the hypothalamus for orexin neurons, suggesting that the orexins play a key role in nicotine-mediated effects. While this effect is blocked by both the non-selective nAChR antagonist mecamylamine and the α4β2 nAChR antagonist DHβE, DHβE alone increased medial hypothalamic orexin neuron activation, but blocked nicotine-induced activation (Pasumarthi et al., 2006) , suggesting that there is endogenous cholinergic regulation of the orexin system. Nicotine-induced activation of orexin neurons appears to be specific to hypothalamic projections to the basal forebrain and paraventricular thalamus (Pasumarthi & Fadel, 2008) . In addition to systemic nicotine administration, orexin neurons can also be activated by local nicotine application to the hypothalamus which produces increased ACh and glutamate efflux in the hypothalamus (Pasumarthi & Fadel, 2010) . These results demonstrate interactions between orexin, which 
Chronic Nicotine and Orexin
Studies of chronic nicotine administration have shown alterations in regulation of hypocretin gene expression and orexin peptides ( Figure 4 ). Chronic nicotine administration (14 days) increases levels of mRNA encoding the prepro-orexin peptide and orexin receptors (Kane et al., 2000) . Blockade of nAChRs in nicotine-exposed rats decreases orexin neuron activation (Simmons et al., 2016) . Measurements of protein show that in the DMH, chronic nicotine increase both OX-A and OX-B, while OX-B is elevated in the paraventricular nucleus (Kane et al., 2000) . However, chronic nicotine also decreases hypothalamic bindings sites available for OX-A (Kane, Parker, & Li, 2001) . This desensitization appears to occur by obscuring binding sites but without internalization because OX-A continued to bind, but with lower affinity (Kane et al., 2001) . Although a more direct demonstration of the exact mechanism of nicotine-induced decrease in binding sites has never been reported in the literature, these results demonstrate that chronic nicotine administration has regulatory effects on both hypocretin gene expression and levels of orexin peptide.
Orexin as a Therapeutic Target for Nicotine Dependence

Nicotine Self-Administration
Preclinical studies of orexin as a potential therapeutic target for nicotine addiction have found effects of both selective and non-selective (dual) orexin receptor antagonists ( Table 1 ).
The first direct demonstration of a role for orexins in nicotine seeking behaviour involved administration of the OX1 receptor antagonist SB-334867 systemically and into the insular cortex (Hollander, Lu, Cameron, Kamenecka, & Kenny, 2008) . OX1 receptor antagonism selectively suppressed the number of nicotine infusions earned on fixed-ratio-5 (FR5) and gene expression and finding decreased Hcrtr1 in the rostral LH immediately after nicotine selfadministration but not 5 h after a self-administration session, while arcuate nucleus had increased Hcrtr1 mRNA 5 h but not immediately after self-administration. These consistent results from different groups provided strong indications that the orexins might be a potential target for the treatment of nicotine addiction.
Reinstatement of Nicotine Seeking
In addition to regulating self-administration of nicotine, it has also been shown that orexin signaling plays a role in the reinstatement of nicotine seeking but results have not been consistent. , 2013) . However, it has been shown that a different selective OX2 receptor antagonist (SORA-18) was able to reduce cue-induced reinstatement in rats, but not nicotineprimed reinstatement or PR self-administration (Uslaner et al., 2014) . These studies suggest that the role of orexin signaling in reinstatement behaviours is inconsistent and may depend on the proximal cause of reinstatement or the behavioural model used. In both rats and mice, cueinduced reinstatement has been reduced using orexin receptor antagonists, but it is unclear whether the OX2 receptor is involved. While these results are suggestive of a role for the orexins in cue-induced reinstatement for nicotine, the relatively small number of studies and the variance in training protocols (Table 1) makes it difficult to draw strong conclusions.
Withdrawal and Motivation
Preclinical studies have also demonstrated roles for orexin signaling in other nicotine- mg/kg dose of SORA-18, which has greater potency than TCS-OX2-29 (Hirose et al., 2003; Uslaner et al., 2014) . The dual orexin receptor antagonist, TCS 1102, also attenuated nicotinepotentiated PR responding and nicotine-induced reinstatement for sucrose pellets (Winrow et al., 2010) . These results also provide support for a potential use for orexin receptor antagonists in treating nicotine addiction because they might reduce symptoms of withdrawal or reduce other reward-related nicotine responses.
Divergent Findings
However, we recently reported that the dual orexin receptor antagonist TCS 1102 had no effect on nicotine self-administration, cue-induced reinstatement, nicotine-primed reinstatement and had at most a small transient effect on cue and prime-induced reinstatement only after chronic nicotine self-administration (Khoo, McNally, & Clemens, 2017) . Although TCS 1102 has previously been shown to be effective in reducing behavioural responses to nicotine (Winrow et al., 2010) and we found that intracerebroventricular TCS 1102 could attenuate OX-A-induced increases in feeding behaviour, we found no evidence of any effect of dual orexin receptor antagonism that could have clinical relevance. We suspect that this discrepancy between our study and previous findings may be due to several differences in protocols. For example, our rats were trained on FR1, while previous studies have generally used FR5 schedules of reinforcement and food pre-training protocols (Hollander et al., 2008; LeSage et al., 2010; Uslaner et al., 2014) . In our study, rats were trained to make nosepokes for nicotine for the entire duration of training with no period of operant responding for food (Khoo et al., 2017) . This may have resulted in relatively lower levels of motivation in our animals. It has previously been argued that nicotine has relatively weak primary reinforcing properties but may act to enhance the motivational properties of other reinforcers and conditioned stimuli (Chaudhri et al., 2006) . If this is the case, the food pre-training protocols used in previous demonstrations of orexinergic regulation of nicotine seeking or self-administration may have potentiated the motivational properties of the conditioned reinforcers and responses that were ultimately paired with nicotine. It has previously been shown that food pre-training enhances acquisition (Bongiovanni & See, 2008; Clemens, Caillé, & Cador, 2010; Garcia, Lê, & Tyndale, 2014) . For example, sucrose pre-training can facilitate later cueinduced reinstatement of nicotine seeking for rats trained to make nosepokes (Clemens et al., 2010) , but food pre-training does not appear to affect later reinstatement tests in rats trained to press levers ( Garcia et al., 2014) . Differences in pre-training protocols could also explain why relatively few rats in our experiments would self-administer under an FR5 schedule of reinforcement (unpublished observations).
These negative results urge caution in seeking to translate orexin antagonists to the clinic, but they do not necessarily exclude orexin-based therapies for nicotine. In humans, nicotine is often used in combination with other drugs (Cross, Lotfipour, & Leslie, 2017) . For example, nicotine increases alcohol consumption in men (Acheson, Mahler, Chi, & de Wit, 2006; Barrett, Tichauer, Leyton, & Pihl, 2006) and subjective feelings of drunkenness (Kouri, McCarthy, Faust, & Lukas, 2004) , results which have been replicated in animal models (Kalejaiye, Bhatti, Taylor, & Tizabi, 2013; Lê, Funk, Lo, & Coen, 2014) . Nicotine use is also associated with using or becoming dependent on cannabis (Taylor et al., 2017) , cocaine (Budney, Higgins, Hughes, & Bickel, 1993; Gorelick, Simmons, Carriero, & Tashkin, 1997) and methamphetamine (Grant et al., 2007) . Using multiple drugs might increase the motivational salience and render nicotine subject to orexinergic regulation. Other drugs of abuse also have stronger evidence for orexinergic regulation and there is currently a clinical trial for using the dual orexin receptor antagonist, suvorexant, in the treatment of cocaine dependence (The University of Texas Health Science Center, 2016). However, further preclinical studies in animal models of polydrug use are required to establish whether this is the case.
Human Studies
A few studies in humans have found associations between the orexin system and nicotine (Table 2) . Human studies have reported a negative correlation between orexin plasma concentration and self-reported nicotine craving (von der Goltz et al., 2010) , and reduced Hcrt mRNA expression in blood samples in smokers compared to non-smokers (Rotter et al., 2012) .
Although these studies are consistent, they are limited by their peripheral measurement of orexin peptide or Hcrt mRNA. While the OX-A peptide can diffuse across the blood-brain barrier, OX-B has low lipophilicity and is rapidly metabolised (Kastin & Akerstrom, 1999) .
Genome-wide association studies have found that in Japanese samples, a single-nucleotide polymorphism in the HCRTR2 gene was associated with increased risk of smoking (Nishizawa et al., 2015) . However, results from these studies should be interpreted with caution because it has been argued that genome-wide association studies produce little useful data when examining complex traits (Boyle, Li, & Pritchard, 2017) , although previous studies have yielded associations between targets that are biologically relevant or already targets for current therapeutics (Visscher, Brown, McCarthy, & Yang, 2012) . While Nishizawa et al. (2015) found associations between HCRTR2 polymorphism and smoking, methamphetamine and schizotypal trait scores, but they also found associations with goiter, aortic aneurysm and myeloma. The current small array of human studies of the orexin system and nicotine suggest that there may be some linkage, but this is correlational and further studies in animals and humans are required to better establish whether the orexin system really is involved in nicotine seeking.
Implications for Treatments
There is currently insufficient evidence to recommend orexin-based treatments for smoking. Although there are some promising preclinical results and correlational evidence has (Nishizawa et al., 2015) Legend to Table 2 : Summary of key findings from human studies to date. GWAS, genomewide association study. been found in humans, there are also some inconsistent findings in the preclinical literature that should be addressed. Further studies are required to examine the relationship between an animal's training history and orexinergic regulation of nicotine seeking.
Conclusion
The orexin system has generated much excitement and interest for its therapeutic potential for a variety of disorders. This potential has recently been realised with the approval of suvorexant for insomnia (Coleman, Gotter, Herring, Winrow, & Renger, 2017) and may be realised for cocaine addiction (The University of Texas Health Science Center, 2016). Animal studies show that acute nicotine stimulates orexin neurons and chronic nicotine can have affect the regulation of the orexin system. Preclinical animal models of drug self-administration and seeking have tested orexin antagonists against nicotine less frequently than against other drugs of abuse, but from a relatively small pool of studies there is a mix of both positive and negative findings regarding the efficacy of orexin antagonists on nicotine self-administration and reinstatement. Research with human participants has found some consistent associations between orexin downregulation and nicotine use, as well as genetic associations between a single-nucleotide HCRTR2 polymorphism and smoking, but these results are correlational. For nicotine and orexin, there is currently insufficient evidence that it would be a useful therapeutic target for nicotine addiction but further studies are required to examine the reasons behind differential outcomes in preclinical research and to follow up on the associations that have been found in human studies.
